KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Common Equity (2016 - 2025)

Cardlytics (CDLX) has disclosed Common Equity for 10 consecutive years, with -$6.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity fell 109.3% year-over-year to -$6.5 million, compared with a TTM value of -$6.5 million through Dec 2025, down 109.3%, and an annual FY2025 reading of -$6.5 million, down 109.3% over the prior year.
  • Common Equity was -$6.5 million for Q4 2025 at Cardlytics, down from -$4.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $744.9 million in Q1 2021 and bottomed at -$6.5 million in Q4 2025.
  • Average Common Equity over 5 years is $319.8 million, with a median of $218.5 million recorded in 2022.
  • The sharpest move saw Common Equity surged 447.57% in 2021, then plummeted 109.3% in 2025.
  • Year by year, Common Equity stood at $690.7 million in 2021, then tumbled by 69.36% to $211.6 million in 2022, then plummeted by 36.3% to $134.8 million in 2023, then tumbled by 48.08% to $70.0 million in 2024, then tumbled by 109.3% to -$6.5 million in 2025.
  • Business Quant data shows Common Equity for CDLX at -$6.5 million in Q4 2025, -$4.7 million in Q3 2025, and $58.7 million in Q2 2025.